초록

Pharmaceutical composition comprising both insulin and glucagon can be administered to control and treat diabetes while reducing or eliminating the risk of insulin-induced hypoglycemia.

대표청구항 ▼

The invention claimed is: 1. A method of reducing the risk of hypoglycemia in a diabetes patient who is being treated with insulin or an insulin secretagogue, which method comprises administering to the patient an amount of glucagon that results in a plasma glucagon level in the range achieved by i

The invention claimed is: 1. A method of reducing the risk of hypoglycemia in a diabetes patient who is being treated with insulin or an insulin secretagogue, which method comprises administering to the patient an amount of glucagon that results in a plasma glucagon level in the range achieved by intravenous infusion of glucagon at a rate that is not less than 0.10 ng/kg/min and not more than 5.00 ng/kglmin, wherein glucagon is administered daily as part of a diabetes treatment regimen, and wherein said patient is not suffering hypoglycemic symptoms and has a blood glucose level of from 70-110 mg/dL when said glucagon is administered. 2. The method of claim 1, wherein said glucagon is contained in a device that controls administration of the drug to a patient. 3. The method of claim 2 wherein the device is a pump. 4. The method of claim 3 wherein the pump is programmed to deliver glucagon daily. 5. The method of claim 3 wherein the pump is programmed to administer glucagon is administered within four hours after said patient has last been administered insulin. 6. The method of claim 2 wherein the device is a transdermal delivery device. 7. The method of claim 1, wherein both insulin and glucagon are administered parenterally. 8. The method of claim 1 wherein the secretagogue is a sulfonylurea. 9. The method of claim 8 wherein the secretagogue is acetohexamide, chlorpropamide, tolazamide, tolbutamide, glimepiride, glipizide, or glyburide. 10. The method of claim 1 wherein the secretagogue is a meglitinide. 11. The method of claim 10 wherein the secretagogue is nateglinide or repaglinide. 12. The method of claim 1 wherein glucagon is administered daily at bedtime. 13. The method of claim 7 wherein the patient is unable to sense low blood glucose accurately due to hypoglycemic unawareness.